Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung

被引:84
作者
Licchesi, Julien D. F. [1 ]
Westra, William H. [2 ]
Hooker, Craig M. [1 ]
Herman, James G. [1 ]
机构
[1] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Canc Biol Program, Baltimore, MD 21231 USA
[2] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA
关键词
D O I
10.1158/1078-0432.CCR-07-2033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: According to current models of tumorigenesis, the progression of phenotypic changes culminating in overtly malignant carcinoma is driven by genetic and epigenetic alterations. The recognition of an early form of glandular neoplasia termed atypical adenomatous hyperplasia (AAH), a precursor lesion from which lung adenocarcinomas arise, provides an opportunity for characterizing early epigenetic alterations involved in lung tumorigenesis. Experimental Design: We evaluated AAHs, adjacent normal lung tissue, and synchronous lung adenocarcinomas for promoter hypermethylation of genes implicated in lung tumorigenesis (P16 TIMP3, DAPK, MGMT RAR beta, RASSF1A, and hTERT). Results: For individual genes and the number of genes methylated, we observed a significant increase in the frequency of promoter hypermethylation in the histologic progression from normal to AAH, with low-grade or high-grade atypia, and finally to adenocarcinoma (P-trend <= 0-01). Multifocal AAHs from individual patients had distinct patterns of promoter hypermethylation, suggesting divergent epigenelic field defects. There were statistically significant positive associations for the presence of promoter hypermethylation of individual and multiple genes with advanced histology, with odds ratios between 4.3 and 58.5.p16 conveyed the strongest individual association for promoter hypermethylation when comparing tumor or high-grade AAH to low-grade AAH or normal tissue, with an odds ratio of 45.5 (95% confidence interval, 5.8-360.5). Conclusion: This study shows epigenetic progression in the earliest stages of glandular neoplasia of the lung and has implications for early lung cancer detection.
引用
收藏
页码:2570 / 2578
页数:9
相关论文
共 38 条
[1]   Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers [J].
Agathanggelou, A ;
Dallol, A ;
Zöchbauer-Müller, S ;
Morrissey, C ;
Honorio, S ;
Hesson, L ;
Martinsson, T ;
Fong, KM ;
Kuo, MJ ;
Yuen, PW ;
Maher, ER ;
Minna, JD ;
Latif, F .
ONCOGENE, 2003, 22 (10) :1580-1588
[2]  
[Anonymous], CHEST
[3]  
[Anonymous], CANC FACTS FIG 2007
[4]  
Bachman KE, 1999, CANCER RES, V59, P798
[5]   The 2004 World Health Organization classification of lung tumors [J].
Beasley, MB ;
Brambilla, E ;
Travis, WD .
SEMINARS IN ROENTGENOLOGY, 2005, 40 (02) :90-97
[6]   Gene-promoter hypermethylation as a biomarker in lung cancer [J].
Belinsky, SA .
NATURE REVIEWS CANCER, 2004, 4 (09) :707-717
[7]   Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort [J].
Belinsky, SA ;
Liechty, KC ;
Gentry, FD ;
Wolf, HJ ;
Rogers, J ;
Vu, K ;
Haney, J ;
Kenned, TC ;
Hirsch, FR ;
Miller, Y ;
Franklin, WA ;
Herman, JG ;
Baylin, SB ;
Bunn, PA ;
Byers, T .
CANCER RESEARCH, 2006, 66 (06) :3338-3344
[8]   Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer [J].
Belinsky, SA .
CARCINOGENESIS, 2005, 26 (09) :1481-1487
[9]   Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis [J].
Belinsky, SA ;
Nikula, KJ ;
Palmisano, WA ;
Michels, R ;
Saccomanno, G ;
Gabrielson, E ;
Baylin, SB ;
Herman, JG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11891-11896
[10]   Epigenetic inactivation of RASSF14 in lung and breast cancers and malignant phenotype suppression [J].
Burbee, DG ;
Forgacs, E ;
Zöchbauer-Müller, S ;
Shivakumar, L ;
Fong, K ;
Gao, BN ;
Randle, D ;
Kondo, M ;
Virmani, A ;
Bader, S ;
Sekido, Y ;
Latif, F ;
Milchgrub, S ;
Toyooka, S ;
Gazdar, AF ;
Lerman, MI ;
Zabarovsky, E ;
White, M ;
Minna, JD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (09) :691-699